Handa Pharmaceuticals, Inc. (6620.TWO)

TWD 69.3

(6.13%)

Market Cap (In TWD)

9.39 Billion

Revenue (In TWD)

1.1 Billion

Net Income (In TWD)

726.88 Million

Avg. Volume

574.2 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
49.9-200.0
PE
21.79
EPS
3.18
Beta Value
1.339
ISIN
TW0006620008
CUSIP
-
CIK
-
Shares
135590748.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Fang-Yu Liu Ph.D.
Employee Count
-
Website
https://www.handapharma.com.tw
Ipo Date
2016-12-30
Details
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products. In addition, the company develops HND-004, a diabetic drug; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.